Polpharma

Polpharma is a dominant, privately-held generic drug manufacturer in Poland and a key regional player in CEE and CIS markets. With over 4,300 employees, five manufacturing plants, and three R&D centers, it produces approximately 400 million medicine packages annually, holding a ~12.5% share of the Polish pharmacy market and a ~33% share of the hospital market. The company is expanding its international presence, notably with a new office in India, and is investing in innovative drug development in areas like ophthalmology and asthma while maintaining a strong foundation in generics and APIs.

Integrated development and manufacturing platform for generic small molecule drugs and active pharmaceutical ingredients (APIs), with focus on complex formulations, patient-friendly drug forms (e.g., injections), and process innovation.

Polpharma competes with global generic giants (e.g., Teva, Sandoz) and regional players in CEE. Its domestic dominance is strong, but international competition is fierce. Its move into complex generics and specialty areas pits it against both other generic companies developing value-added products and originator companies defending niche markets.